Rebiotix, a Minnesota-based biotechnology company, and McMaster Children's Hospital, based in Ontario, Canada, have started the PediFETCh clinical trial, according to an IBD News Today report.
Here are three notes:
1. The PediFETCh — Pediatric FEcal microbial Transplant for Ulcerative Colitis — trial is a randomized clinical trial assessing fecal microbial transplant in children with ulcerative colitis.
2. The first pediatric patient in the trial has started receiving treatment.
3. The FMT procedure performed within the trial is based on RBX2660, Rebiotix's lead drug platform for microbial restoration therapy.